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Purpose: Pterygium is a common fibro-vascular-related eye disease. The fibroblast
growth factor 21 (FGF21) helps reduce neovascularization. Previous studies have shown
that the serum level of FGF21 correlates with vascular eye diseases such as diabetic
retinopathy and retinopathy of prematurity. In this study, the serum FGF21 is compared
in patients with and without pterygium.
Methods: This descriptive-analytical cross-sectional study examines individuals with
pterygium who visited the Ophthalmology Clinic of Khatam-al-Anbia Hospital in
Mashhad, Iran, during 2017–2018. Control subjects were selected from healthy people
without pterygium disease. Patients with a history of acute illness, chronic liver and
kidney disease, diabetes, cancer, malnutrition and drug use, women who were pregnant
or breastfeeding, and subjects who were taking anticonvulsants or glucocorticoids were
excluded as these may affect insulin and glycosuria levels. Sixty people (30 in each
group) were chosen using the convenient sampling method. Intravenous blood samples
were taken from all patients. After preparing the patients, the freeze was checked using
the enzyme-linked immunosorbent assay (ELISA) method after samples had been taken.
Data were analyzed by SPSS using an independent t-test, Mann–Whitney, Chi-square,
Kruskal–Wallis, and Kolmogorov–Smirnov tests (𝛼 = 0.05).
Results: The serumFGF21 levels were 319.09± 246.93 pg/ml and 608.88± 449.81 pg/ml
(P = 0.005) in the pterygium group and control subjects, respectively. The average serum
FGF21 was 281.55 ± 40.74 pg/ml in males and 361.375 ± 10.298 pg/ml in females in the
pterygium group. The difference was not statistically significant (P = 0.19)
Conclusion: Our study showed that FGF21 levels were lower in patients with pterygium
than the control subjects to a statistically significant level.
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INTRODUCTION
Pterygium thickens on the bulbar conjunctiva as
a prominent triangular mass and extends to the
cornea. This condition involves degeneration of
the elastoid collagen and invades the cornea
with subepithelial fibrovascular tissue. This dis-
ease occurs in specific geographical zones with
varying prevalence; with outdoor work increasing
its incidence by 1.5 times. The reason for this
is unknown. Generally, pterygium is considered
a trivial problem unless it adversely affects the
visual axis, which is dependent on its location.
However, it can be concerning for patients due to
its unusual and inflammatory appearance.[1, 2] The
decision to undergo surgery varies according to
the growth speed of the mass and the degree of
astigmatism. It is recommended to avoid surgery
for only the cosmetic reasons.[3] Despite numerous
methods for treating pterygium, there is a 30–70%
recurrence rate, which drives ocular surgeons to
use adjunct medicines.[3]
The fibroblast growth factor (FGF) group
includes 22 members, each of which is divided
into seven subfamilies based on homology and
phylogeny. The subgroups of FGF19 including
FGF15, FGF21, and FGF23 play a significant
role in endocrine performance and metabolizing
carbohydrates and lipids.[4] Growth factors play
an important role in many ocular diseases. In
a study on mice, the administration of FGF21,
which is a member of this family, reduced
angiogenesis through adiponectin. In doing
so, FGF21 increases adiponectin and as a
result, decreases TNF𝛼.[5, 6] The serum level
of FGF21 is reduced in diabetes type I but
is increased in diabetes type II. The unusual
increase of FGF21 in diabetes type II is a
compensatory protective response[7] that induces
hypoglycemia and improves sugar metabolism in
the body.[8–10] Recent studies have indicated
that serum FGF21 is lower in patients with
type I diabetes mellitus and in neonates with
retinopathy of prematurity compared to a healthy
control group.[8, 10, 11] Moreover, some studies
indicated that the administration of FGF21
reduced LDL, triglycerides, and cholesterol
and increased HDL.[9] Hence, FGF21 has a
significant impact on improving obesity- and
diabetes-related complications.[8] Considering
the prevalence of pterygium, the fibrovascular
nature of pterygium, the protective effects
of FGF21 on angiogenesis, and the lack of
published studies so far, the present researchers
decided to compare the serum FGF21 in the
blood samples of patients with and without
pterygium.
METHODS
The study population included patients with clinical
signs of pterygium who had presented to the Oph-
thalmology Clinic of Khatam-Al Anbia Hospital in
Mashhad, Iran, during 2017–2018. All volunteered
to participate in the study, were not under any
drug regimen, and had no specific disease. The
control group included patients without pterygium
who presented to the aforementioned clinic and
accepted to participate in the study. They also were
not under any drug regimen, had no underlying
disease, and were matched for age and gender
with the case group [Table 1]. Patients who did
not wish to participate or had a history of acute
illness, chronic liver and kidney disease, diabetes,
cancer, malnutrition, drug use, were pregnant,
breastfeeding, or were taking anticonvulsants or
glucocorticoids were excluded as these may affect
insulin and glycosuria levels. Participants were
selected using the convenient sampling method.
Patients diagnosed with pterygium by an oph-
thalmologist were assigned to the case group.
The same number of subjects who matched the
case group in terms of age and gender were
assigned to the control group. Given the lack of
any similar study, we used a sample volume of
30 patients per group as a pilot study. Having
selected the case and control subjects, 5 cc
of venous blood was taken by a phlebotomist
from the radial vein of each participant after
fasting for 12 h. The blood samples were first
centrifuged for 20 min at 3000 rpm, and the
overlying serum was isolated. Care was taken to
have samples that were not severely hemolyzed,
blurred, lipemic, or infected with microbes. The
isolated sera were divided into small portions
and kept at –20∘C until the testing began. The
samples were examined using the enzyme-linked
immunosorbent assay (ELISA) method with spe-
cial kits for human studies (China Crystaldi Co.,
purchased from Pardisa Tebazema Co., Mashhad,
Iran). Then, the total serum rate of FGF21 was
compared between the two groups. As there
is a relationship between FGF21 and metabolic
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Table 1. Comparison of mean age and gender in pterygium and control groups
Group Pterygium patients Control patients Independent t-test
Variable Mean ± SD Mean ± SD t = 1.8
Age 42.21 ± 12.32 38.28 ± 10.83 p = 0.08






Table 2. Comparison of mean serum FGF21 in patients with pterygium in terms of gender
Group Male Female Mann–Whitney test
Variable Mean ± SD Mean ± SD
Serum FGF21 281.55 ± 40.74 361.375 ± 10.298 Z = 2.95
p = 0.198
FGF, fibroblast growth factor; SD, standard deviation
factors like cholesterol and triglycerides, these
factors were also measured and analyzed. The
data were analyzed with SPSS using the Chi-
square and Mann–Whitney tests (𝛼 = 0.05). The
two groups were matched for age and gen-
der using the Kruskal–Wallis and Mann–Whitney
tests, respectively. As the FGF21 data was not
normally distributed, the nonparametric incon-
sistency test of Mann–Whitney was used. The
required data were collected using a researcher-
made questionnaire developed based on our
research goals. This checklist included items on
their history with pterygium, age group, gender,
and serum level of FGF21. The research proposal
was approved by the Research Council of the
School of Medicine and the Committee of Ethics
in Human Research at the Birjand University of
Medical Sciences. The research goals and proce-
dures were thoroughly discussed with each patient
and assured they would remain anonymous and
that their information would be kept confidential.
Informed written consent was obtained from each
patient. The participants could leave the study
at any stage, with this not affecting their treat-
ment.
RESULTS
This study consisted of 60 participants including
30 patients with pterygium and 30 healthy indi-
viduals forming the control group. No participants
had any relevant medical history or were taking
any medications that would impact our study’s
outcomes.
In the pterygium group, 96.7% of the patients
had pterygium in the ocular nasal zone, 43.3% of
patients had only one affected eye, while for the
remaining 56.7%, both eyes were affected.
Patients with diabetes mellitus were excluded
from the study. This was because it has been
shown that the serum FGF21 level has a positive
and negative correlation with type 2 and type 1
diabetes mellitus, respectively.
Regarding the comparison of serum FGF21 in
patients with and without pterygium, the results
of the Mann–Whitney test showed a statistically
significant difference in the mean of the serum
FGF21 between the pterygium (319.09 ± 246.93)
and control (608.88 ± 449.81) groups (P = 0.005).
Moreover, regarding the comparison of serum
FGF21 in pterygium patients in terms of gender,
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Table 3. Comparison of mean cholesterol, creatinine, urea, SGOT, SGPT, HDL, and LDL between the pterygium and control
groups
Group Pterygium patients Control patients Independent t–test / Mann–Whitney test
Variable Mean ± SD Mean ± SD
Cholesterol 206.86 ± 50.77 155.53 ± 32.15 t = 4.67
p < 0.0001
Triglyceride 138.66 ± 102.83 98.90 ± 50.52 Z = 2.17
p = 0.03
LDL 101.71 ± 30.62 76.00 ± 22.26 t = 3.60
p = 0.001
HDL 48.17 ± 22.03 57.33 ± 33.7 Z = 1.28
p = 0.2
Creatinine 0.92 ± 0.18 0.95 ± 0.14 Z = 1.28
p = 0.2
Urea 28.07 ± 7.94 24.43 ± 6.86 t = 1.58
p = 0.07
SGOT 26.58 ± 9.96 21.96 ± 6.90 Z = 1.67
p = 0.09
SGPT 28.15 ± 17.14 23.21 ± 9.81 Z = 0.77
p = 0.42
HDL, high-density lipoprotein; LDL, low-density lipoproteins; SD, standard deviation; SGOT, serum glutamic-oxaloacetic
transaminase
the Mann–Whitney test indicated no significant
difference between males (281.55 ± 40.74) and
females (361.375 ± 10.298) (P = 0.198) [Table 2].
A regular diet one week before the sampling
session was enforced to more accurately evaluate
the lipid serum levels after a 12-h fasting period.
An independent t-test revealed a significant
difference in the mean cholesterol levels between
the cases (206.86 ± 50.77) and controls (155.53
± 32.15), being significantly higher in patients with
pterygium (P < 0.0001). The corresponding figures
for LDL were 101.71 ± 30.62 and 76.00 ± 22.26
(P = 0.001). The results of the Mann–Whitney
test further demonstrated a significant difference
in triglyceride levels in patients with pterygium
(138.66 ± 102.83) compared to the control group
(98.90 ± 50.52; P = 0.03); however, there was no
significant difference in terms of the HDL levels
between the two groups (48.17 ± 22.0 and 57.33
± 33.7, respectively; P = 0.2).
Liver and kidney functions were also assessed,
as FGF21 secretes from and exerts through these
two organs, respectively. The Mann–Whitney test
suggested no significant difference in creatinine
levels between the pterygium (0.92 ± 0.18) and
control (0.95 ± 0.14) groups (P = 0.2). An inde-
pendent t-test showed no significant difference in
the urea level between the two groups (28.07 ±
7.94 and 24.43 ± 6.86, respectively; P = 0.07).
The same test suggested no significant difference
in the serum glutamic–oxaloacetic transaminase
(SGOT) and serum glutamic–pyruvic transaminase
(SGPT) levels between the case and control groups
(P = 0.09 and P = 0.42, respectively) [Table
3].
DISCUSSION
Our findings showed a significant difference in
serum FGF21 between the pterygium and con-
trol groups. The serum FGF21 was significantly
lower in patients with pterygium compared to
non-pterygium patients (P = 0.005). Fibrovascu-
lar proliferation, along with several inflammatory
factors, are important in pterygium pathogene-
sis. Increased vascular endothelial growth factor
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(VEGF) levels have been reported in immunohis-
tological studies, with bevacizumab being used to
improve the outcomes and reduce recurrences of
pterygium.[12] However, FGF21 acts independently
of VEGF.
Our findings regarding the effects of FGF21
on inhibiting angiogenesis are consistent with
the results of the study by Fu et al in which
they observed the inhibition of angiogenesis by
systemically administering this factor to mice.
This inhibitory effect was exerted through
adiponectin and TNF𝛼 and was seen to
be independent of VEGF.[6] In humans, the
administration of FGF21 increases adiponectin
in a dose-dependent form.[13] Low levels of
adiponectin in human blood circulation may
be associated with neovascularization-related
diseases in the eyes.[14, 15] Our results are
consistent with the protective effects of this
factor in neovascularization-related eye diseases,
as described by previous studies. Chavez et al
compared the serum FGF21 in thin, fat, fasting
blood sugar impaired and diabetic patients and
found that people with type II diabetes had
higher serum FGF21 compared to other groups,
linking this to the status of insulin resistance.[16]
Also, in a study by Kralisch et al, the mean
concentration of serum FGF21 in patients with type
II diabetes mellitus was 2.1 times higher compared
to the healthy controls.[17] The level of this factor
decreases in type I diabetes as it is synthesized
in the liver and pancreas and people with type I
diabetes have impaired pancreas function. The
increased level of FGF21 in type II diabetes is due
to the compensatory effect induced by insulin
resistance in these patients.[18]
Therefore, despite the beneficial effects of
this factor on lipid metabolism[9] and reducing
angiogenesis, it is asserted that tissue resistance
to FGF21 in obesity[19], fatty liver, and related
metabolic disorders[19, 20] are responsible for an
increased serum level of FGF21. The same patho-
genesis is suggested regarding insulin function in
type 2 diabetes mellitus.
This is similar to type 1 diabetes mellitus in
which auto-immune degeneration of the pancreatic
cells results in decreased insulin levels. In type 2
diabetes mellitus, the tissue resistance to insulin
leads to hyperinsulinemia, and the physiologic
level of insulin is not effective in controlling the
serum glucose level.[20]
Given that the serum level of this factor is
affected by various types of diabetes, people
with diabetes were excluded from our study. Our
findings further showed a significant difference in
the mean cholesterol level, mean triglyceride level,
and mean LDL level between the pterygium and
control patients. The means of these three indices
were significantly higher in patients with pterygium
compared to the control group. This study took into
account the probability of such metabolic changes
in pterygium patients.
In line with our results, Malekifar et al[21] showed
that pterygium is significantly related to ischemic
heart disease and obesity. Accordingly, it can be
suggested that pterygium is not an isolated dis-
ease and can present as a metabolic condition.[22]
However, further studies are needed to confirm this
idea.
Other observations in South Korea revealed
a relationship between obesity and pterygium.
They showed that hyperlipidemia and obesity
are more prevalent in patients with pterygium
due to lower FGF21 serum levels.[23] Moreover,
consistent with our findings, a study by Wente
et al showed that FGF21 reduced lipid levels and
improved lipid metabolism in rats.[24] In the study
by Zhang et al, the administration of FGF21 to
type I diabetics diminished apoptosis, improved
lipid metabolism, reduced fat accumulation in the
organs, and decreased oxidative stress. Overall,
complications in these patients were reduced.[8]
In the current study, the reduced level of FGF21
in patients with pterygium was associated with
impaired lipid metabolism. If future studies con-
firm this finding, pterygium can be considered a
cardiovascular risk factor. The serum FGF21 level
was not significantly different between males and
females in our study, while in Zibar’s study, the
serum FGF21 was higher in type I diabetic females
compared to males. However, the serum FGF21
was not different betweenmales and females in the
healthy subjects, a finding that is consistent with
our results.[25]
We found no significant difference between the
liver enzymes, urea, and creatinine between the
two study groups. Since FGF21 is produced by the
liver and excreted by the kidney, the difference
of this factor between the two groups does not
appear to be related to liver and kidney function.
In Panchapak’s study conducted in Australia
on 3,564 patients aged 49 years or older, 7.3%
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of the patients had pterygium and 69.5% had
pinguecula, with the prevalence being significantly
higher among males than females.[26] The find-
ings demonstrated that in more than 96% of the
patients, the pterygium site was the ocular nasal
zone. This is consistent with our study, in which
pterygium was more likely to occur in the ocular
nasal zone. Most patients had unilateral pterygium.
Overall, 43.3% of patients were affected with ptery-
gium in only one eye and 56.7% in both eyes. Find-
ing appropriate pharmacological therapy options
for patients who do not wish to undergo surgery
is a significant priority.[27] It is hoped that some
non-surgical treatment methods and prophylactic
procedures will soon be introduced.
Regarding the high prevalence of cardiovascular
disorders and its resulting mortality and morbidity,
there is growing attention toward new cardiovascu-
lar risk factors such as inflammatory cytokines and
hair growth on the external ear, even in younger
adults. The results of this study and its association
with obesity and ischemic heart disease as seen
in previous studies, suggest that pterygium should
be considered a cardiovascular risk factor.[28] If
pterygium was included in cardiovascular screen-
ing tests, cardiovascular complications might be
reduced.
In conclusion, our findings suggest that low
serum FGF21 in patients with pterygium affects
the condition and may be a protective factor.
In addition, impaired lipid metabolism should be
taken into account in these patients.
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